Alternative paradigms for ion channelopathies: Disorders of ion channel membrane trafficking and posttranslational modification

Annual Review of Physiology

Volumn 77, Issue , 2015, Pages 505-524

  Curran, Jerry ^a,b   Mohler, Peter J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Arrhythmia; Cytoskeleton; Heart failure; Phosphorylation; Protein trafficking; Targeting

Indexed keywords

CYTOSKELETON PROTEIN; ION CHANNEL; SCAFFOLD PROTEIN;

ARTICLE; CELL MIGRATION; CHANNELOPATHY; HEART FAILURE; HEART MUSCLE EXCITABILITY; HUMAN; LUPUS LIKE SYNDROME; MYOCARDIAL DISEASE; NITROSYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; BIOLOGICAL MODEL; CELL MEMBRANE; CYTOSKELETON; GENETICS; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT;

CELL MEMBRANE; CHANNELOPATHIES; CYTOSKELETON; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT;

EID: 84922802011     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021014-071838     Document Type: Article

References (138)

1. Hille B. 2001. Ion Channels of Excitable Membranes. Sunderland, MA: Sinauer. 3rd ed.
2. Fahlke C. 2000. Molecular mechanisms of ion conduction in ClC-type chloride channels: lessons from disease-causing mutations. Kidney Int. 57:780-86
3. Aguilar-Bryan L, Clement JP IV, Gonzalez G, Kunjilwar K, Babenko A, Bryan J. 1998. Toward understanding the assembly and structure of KATP channels. Physiol. Rev. 78:227-45
4. CoetzeeWA, Amarillo Y, Chiu J, Chow A, Lau D, et al. 1999. Molecular diversity of K+ channels. Ann. N. Y. Acad. Sci. 868:233-85
5. Kline CF, KurataHT,HundTJ, Cunha SR,KovalOM,et al. 2009. Dual role ofKATP channelC-terminal motif in membrane targeting and metabolic regulation. Proc. Natl. Acad. Sci. USA 106:16669-74
6. Li J, Kline CF, Hund TJ, Anderson ME, Mohler PJ. 2010. Ankyrin-B regulates Kir6.2 membrane expression and function in heart. J. Biol. Chem. 285:28723-30
7. Davies JC, Alton EW, Bush A. 2007. Cystic fibrosis. BMJ 335:1255-59
8. Meregalli PG,Tan HL, ProbstV,Koopmann TT, TanckMW, et al. 2009. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 6:341-48
9. Meregalli PG,Wilde AA, Tan HL. 2005. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc. Res. 67:367-78
10. Probst V,Wilde AA, Barc J, Sacher F, Babuty D, et al. 2009. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ. Cardiovasc. Genet. 2:552-57
11. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, et al. 2008. Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Investig. 118:2260-68
12. Hu D, Barajas-Martinez H, Burashnikov E, SpringerM,Wu Y, et al. 2009. Amutation in the β3 subunit of the cardiac sodium channel associated with BrugadaECGphenotype. Circ. Cardiovasc. Genet. 2:270-78
13. Yang Y, Yang Y, Liang B, Liu J, Li J, et al. 2010. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am. J. Hum. Genet. 86:872-80
14. Morita H, Wu J, Zipes DP. 2008. The QT syndromes: long and short. Lancet 372:750-63
15. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. 2008. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol. 19:1289-93
16. Imai M, Nakajima T, Kaneko Y, Niwamae N, Irie T, et al. 2014. A novel KCNQ1 splicing mutation in patients with forme fruste LQT1 aggravated by hypokalemia. J. Cardiol. 64:121-26
17. Keller SH, Platoshyn O, Yuan JX. 2005. Long QT syndrome-Associated I593R mutation in HERG potassium channel activates ER stress pathways. Cell Biochem. Biophys. 43:365-77
18. Silvis MR, Picciano JA, Bertrand C, Weixel K, Bridges RJ, Bradbury NA. 2003. A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates. J. Biol. Chem. 278:11554-60
19. Dobson CM. 2003. Protein folding and misfolding. Nature 426:884-90
20. Riordan JR. 2005. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67:701-18
21. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, et al. 2006. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113:365-73
22. Gui J, Wang T, Jones RP, Trump D, Zimmer T, Lei M. 2010. Multiple loss-of-function mechanisms contribute to SCN5A-related familial sick sinus syndrome. PLOS ONE 5:e10985
23. Bidaud I, Mezghrani A, Swayne LA, Monteil A, Lory P. 2006. Voltage-gated calcium channels in genetic diseases. Biochim. Biophys. Acta 1763:1169-74
24. Herfst LJ, Rook MB, Jongsma HJ. 2004. Trafficking and functional expression of cardiac Na+ channels. J. Mol. Cell. Cardiol. 36:185-93
25. Vacher H, Trimmer JS. 2012. Trafficking mechanisms underlying neuronal voltage-gated ion channel localization at the axon initial segment. Epilepsia 53(Suppl. 9):21-31
26. Ficker E, Dennis A, Kuryshev Y, Wible BA, Brown AM. 2005. HERG channel trafficking. Novartis Found. Symp. 266:57-69; discussion 70-74, 95-99
27. Bukau B, Horwich AL. 1998. The Hsp70 and Hsp60 chaperone machines. Cell 92:351-66
28. Ficker E, Dennis AT, Wang L, Brown AM. 2003. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. 92:e87-100
29. Barhanin J, Lesage F, Guillemare E, Fink M, LazdunskiM, Romey G. 1996. KVLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current. Nature 384:78-80
30. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, et al. 1996. Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel. Nature 384:80-83
31. Xu X, Kanda VA, Choi E, Panaghie G, Roepke TK, et al. 2009. MinK-dependent internalization of the IKs potassium channel. Cardiovasc. Res. 82:430-38
32. BianchiL, ShenZ,DennisAT, Priori SG,NapolitanoC, et al. 1999. Cellular dysfunction ofLQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. Hum. Mol. Genet. 8:1499-507
33. Yamashita F, Horie M, Kubota T, Yoshida H, Yumoto Y, et al. 2001. Characterization and subcellular localization ofKCNQ1with a heterozygous mutation in theCterminus. J. Mol. Cell. Cardiol. 33:197-207
34. Biliczki P, Girmatsion Z, Brandes RP, Harenkamp S, Pitard B, et al. 2009. Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs α-subunit interaction. Heart Rhythm 6:1792-801
35. Labro AJ, Boulet IR,Timmermans JP, Ottschytsch N, Snyders DJ. 2010. The rate-dependent biophysical properties of the LQT1 H258R mutant are counteracted by a dominant negative effect on channel trafficking. J. Mol. Cell. Cardiol. 48:1096-104
36. Li D, Takimoto K, Levitan ES. 2000. Surface expression of Kv1 channels is governed by a C-terminal motif. J. Biol. Chem. 275:11597-602
37. Shi G, Nakahira K, Hammond S, Rhodes KJ, Schechter LE, Trimmer JS. 1996. βsubunits promote K+ channel surface expression through effects early in biosynthesis. Neuron 16:843-52
38. Schmitt N, Schwarz M, Peretz A, Abitbol I, Attali B, Pongs O. 2000. A recessive C-terminal Jervell and Lange-Nielsen mutation of the KCNQ1 channel impairs subunit assembly. EMBO J. 19:332-40
39. Sato A, Arimura T,Makita N, Ishikawa T, Aizawa Y, et al. 2009. Novel mechanisms of trafficking defect caused by KCNQ1 mutations found in long QT syndrome. J. Biol. Chem. 284:35122-33
40. Volkers L, Rook MB, Das JH, Verbeek NE, Groenewegen WA, et al. 2009. Functional analysis of novel KCNQ2 mutations found in patients with Benign Familial Neonatal Convulsions. Neurosci. Lett. 462:24-29
41. Su J, Cao X, Wang K. 2011. A novel degradation signal derived from distal C-terminal frameshift mutations of KCNQ2 protein which cause neonatal epilepsy. J. Biol. Chem. 286:42949-58
42. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, et al. 1998. A potassium channel mutation in neonatal human epilepsy. Science 279:403-6
43. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, et al. 1997. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat. Genet. 15:186-89
44. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. 1995. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803
45. Wilson AJ, Quinn KV, Graves FM, Bitner-Glindzicz M, Tinker A. 2005. Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1). Cardiovasc. Res. 67:476-86
46. Grant B, Zhang Y, Paupard MC, Lin SX, Hall DH, Hirsh D. 2001. Evidence that RME-1, a conserved C. elegans EH-domain protein, functions in endocytic recycling. Nat. Cell Biol. 3:573-79
47. Hurley JH. 2010. The ESCRT complexes. Crit. Rev. Biochem. Mol. Biol. 45:463-87
48. Zivony-Elboum Y, Westbroek W, Kfir N, Savitzki D, Shoval Y, et al. 2012. A founder mutation in Vps37A causes autosomal recessive complex hereditary spastic paraparesis. J. Med. Genet. 49:462-72
49. Dinour D, Davidovitz M, Levin-Iaina N, Lotan D, Cleper R, et al. 2009. Truncating mutations in the chloride/proton ClC-5 antiporter gene in seven Jewish Israeli families with Dent's 1 disease. Nephron Clin. Pract. 112:c262-67
50. Piwon N, Gunther W, Schwake M, Bosl MR, Jentsch TJ. 2000. ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408:369-73
51. Devuyst O, Jouret F, Auzanneau C, Courtoy PJ. 2005. Chloride channels and endocytosis: new insights from Dent's disease and ClC-5 knockout mice. Nephron Physiol. 99:p69-73
52. The Cardiac Arrhythmia Suppression Trial II Investigators. 1992. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med. 327:227-33
53. Brooks MM, Gorkin L, Schron EB,Wiklund I, Campion J, Ledingham RB. 1994. Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). Control. Clin. Trials 15:437-49
54. Zimmer T, Surber R. 2008. SCN5A channelopathies-An update on mutations and mechanisms. Prog. Biophys. Mol. Biol. 98:120-36
55. Abriel H. 2010. Cardiac sodium channel Nav1.5 and interacting proteins: physiology and pathophysiology. J. Mol. Cell. Cardiol. 48:2-11
56. Pfahnl AE, Viswanathan PC,Weiss R, Shang LL, Sanyal S, et al. 2007. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm 4:46-53
57. Tan BH, Valdivia CR, Song C, Makielski JC. 2006. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant backgroundQ1077 and rescue bymexiletine. Am. J. Physiol. Heart Circ. Physiol. 291:H1822-28
58. Valdivia CR, AckermanMJ, Tester DJ, Wada T, McCormack J, et al. 2002. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc. Res. 55:279-89
59. Duff HJ,Offord J,West J,Catterall WA. 1992. Class I and IV antiarrhythmic drugs and cytosolic calcium regulatemRNAencoding the sodium channelαsubunit in rat cardiac muscle. Mol. Pharmacol. 42:570-74
60. Curran J, Mohler PJ. 2011. Coordinating electrical activity of the heart: ankyrin polypeptides in human cardiac disease. Expert Opin. Ther. Targets 15:789-801
61. Bennett V, Davis J. 1983. Spectrin and ankyrin in brain. Cell Motil. 3:623-33
62. Bennett V, Stenbuck PJ. 1979. Identification and partial purification of ankyrin, the high affinity membrane attachment site for human erythrocyte spectrin. J. Biol. Chem. 254:2533-41
63. Kizhatil K, Sandhu NK, Peachey NS, Bennett V. 2009. Ankyrin-B is required for coordinated expression ofβ-2-spectrin, theNa/K-ATPase and the Na/Ca exchanger in the inner segment of rod photoreceptors. Exp. Eye Res. 88:57-64
64. Kline CF, Wright PJ, Koval OM, Zmuda EJ, Johnson BL, et al. 2013. βIV-Spectrin and CaMKII facilitate Kir6.2 regulation in pancreatic βcells. Proc. Natl. Acad. Sci. USA 110:17576-81
65. Jenkins SM, Bennett V. 2001. Ankyrin-G coordinates assembly of the spectrin-basedmembrane skeleton, voltage-gated sodium channels, and L1 CAMs at Purkinje neuron initial segments. J. Cell Biol. 155:739-46
66. Bennett V. 1978. Purification of an active proteolytic fragment of the membrane attachment site for human erythrocyte spectrin. J. Biol. Chem. 253:2292-99
67. Bennett V, Stenbuck PJ. 1980. Human erythrocyte ankyrin. Purification and properties. J. Biol. Chem. 255:2540-48
68. Ayalon G, Davis JQ, Scotland PB, Bennett V. 2008. An ankyrin-based mechanism for functional organization of dystrophin and dystroglycan. Cell 135:1189-200
69. Kizhatil K, Baker SA, Arshavsky VY, Bennett V. 2009. Ankyrin-G promotes cyclic nucleotide-gated channel transport to rod photoreceptor sensory cilia. Science 323:1614-17
70. Le Scouarnec S, Bhasin N, Vieyres C, Hund TJ, Cunha SR, et al. 2008. Dysfunction in ankyrin-Bdependent ion channel and transporter targeting causes human sinus node disease. Proc. Natl. Acad. Sci. USA 105:15617-22
71. Garrido JJ, Giraud P, Carlier E, Fernandes F, Moussif A, et al. 2003. A targeting motif involved in sodium channel clustering at the axonal initial segment. Science 300:2091-94
72. Pan Z, Kao T, Horvath Z, Lemos J, Sul JY, et al. 2006. A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J. Neurosci. 26:2599-613
73. Sato PY, Coombs W, Lin X, Nekrasova O, Green KJ, et al. 2011. Interactions between ankyrin-G, Plakophilin-2, and Connexin43 at the cardiac intercalated disc. Circ. Res. 109:193-201
74. Lowe JS, Palygin O, Bhasin N, Hund TJ, Boyden PA, et al. 2008. Voltage-gated Nav channel targeting in the heart requires an ankyrin-G dependent cellular pathway. J. Cell Biol. 180:173-86
75. Wang Q, Shen J, Splawski I, AtkinsonD, Li Z, et al. 1995. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80:805-11
76. Mohler PJ, Rivolta I, Napolitano C, LeMaillet G, Lambert S, et al. 2004. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc. Natl. Acad. Sci. USA 101:17533-38
77. Priori SG,Napolitano C,Gasparini M, Pappone C,Della Bella P, et al. 2002. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105:1342-47
78. Hund TJ, Koval OM, Li J,Wright PJ, Qian L, et al. 2010. A βIV-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. J. Clin. Investig. 120:3508-19
79. Mohler PJ, Davis JQ, Bennett V. 2005. Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR microdomain. PLOS Biol. 3:e423
80. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, et al. 2003. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634-39
81. Camors E, Mohler PJ, Bers DM, Despa S. 2012. Ankyrin-B reduction enhances Ca spark-mediated SR Ca release promoting cardiac myocyte arrhythmic activity. J. Mol. Cell. Cardiol. 52:1240-48
82. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, et al. 1995. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am. J. Hum. Genet. 57:1114-22
83. Hund TJ, Mohler PJ. 2008. Ankyrin-based targeting pathway regulates human sinoatrial node automaticity. Channels 2:404-6
84. AyalonG,Hostettler JD, Hoffman J,Kizhatil K, Davis JQ, Bennett V. 2011. Ankyrin-B interactions with spectrin and dynactin-4 are required for dystrophin-based protection of skeletal muscle from exercise injury. J. Biol. Chem. 286:7370-78
85. Bhasin N, Cunha SR, Mudannayake M, Gigena MS, Rogers TB, Mohler PJ. 2007. Molecular basis for PP2A regulatory subunit B56α targeting in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 293:H109-19
86. Healy JA, Nilsson KR, Hohmeier HE, Berglund J, Davis J, et al. 2010. Cholinergic augmentation of insulin release requires ankyrin-B. Sci. Signal. 3:ra19
87. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, et al. 2004. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 53:2719-22
88. Lin X, Liu N, Lu J, Zhang J, Anumonwo JM, et al. 2011. Subcellular heterogeneity of sodium current properties in adult cardiac ventricular myocytes. Heart Rhythm 8:1923-30
89. Gavillet B, Rougier JS,Domenighetti AA, Behar R, BoixelC, et al. 2006. Cardiac sodium channelNav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circ. Res. 99:407-14
90. Williams JC, Armesilla AL, Mohamed TM, Hagarty CL, McIntyre FH, et al. 2006. The sarcolemmal calcium pump,α-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J. Biol. Chem. 281:23341-48
91. Ahern GP, Hsu SF, Klyachko VA, Jackson MB. 2000. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J. Biol. Chem. 275:28810-15
92. Oceandy D, Cartwright EJ, Emerson M, Prehar S, Baudoin FM, et al. 2007. Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation 115:483-92
93. Ueda K, Valdivia C, Medeiros-Domingo A, Tester DJ, Vatta M, et al. 2008. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc. Natl. Acad. Sci. USA 105:9355-60
94. Bankston JR, Sampson KJ, Kateriya S, Glaaser IW, Malito DL, et al. 2007. A novel LQT-3 mutation disrupts an inactivation gate complex with distinct rate-dependent phenotypic consequences. Channels 1:273-80
95. Chang CC, Acharfi S, Wu MH, Chiang FT, Wang JK, et al. 2004. A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. Cardiovasc. Res. 64:268-78
96. Cheng J, Van Norstrand DW, Medeiros-Domingo A, Valdivia C, Tan BH, et al. 2009. α1-Syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current. Circ. Arrhythm. Electrophysiol. 2:667-76
97. Lajoie P, Nabi IR. 2010. Lipid rafts, caveolae, and their endocytosis. Int. Rev. Cell Mol. Biol. 282:135-63
98. Balijepalli RC, Kamp TJ. 2008. Caveolae, ion channels and cardiac arrhythmias. Prog. Biophys. Mol. Biol. 98:149-60
99. Harvey RD, Hell JW. 2013. CaV1.2 signaling complexes in the heart. J. Mol. Cell. Cardiol. 58:143-52
100. Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ. 2006. Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for β2-Adrenergic regulation. Proc. Natl. Acad. Sci. USA 103:7500-5
101. Ostrom RS, Bundey RA, Insel PA. 2004. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes. J. Biol. Chem. 279:19846-53
102. Shibata EF, Brown TL, Washburn ZW, Bai J, Revak TJ, Butters CA. 2006. Autonomic regulation of voltage-gated cardiac ion channels. J. Cardiovasc. Electrophysiol. 17(Suppl. 1):34-42
103. Steinberg SF. 2004. β2-Adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts. J. Mol. Cell. Cardiol. 37:407-15
104. Venema VJ, JuH, Zou R, Venema RC. 1997. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain. J. Biol. Chem. 272:28187-90
105. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, et al. 2007. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 4:161-66
106. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, et al. 2006. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114:2104-12
107. Cheng J, Valdivia CR, Vaidyanathan R, Balijepalli RC, Ackerman MJ, Makielski JC. 2013. Caveolin-3 suppresses late sodium current by inhibiting nNOS-dependent S-nitrosylation of SCN5A. J. Mol. Cell. Cardiol. 61:102-10
108. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2-220
109. Marban E. 1999. Heart failure: the electrophysiologic connection. J. Cardiovasc. Electrophysiol. 10:1425-28
110. Kääb S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, et al. 1996. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ. Res. 78:262-73
111. Kääb S, Dixon J,Duc J, Ashen D, NabauerM, et al. 1998. Molecular basis of transient outward potassium current downregulation in human heart failure: A decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98:1383-93
112. Narayan SM, Bayer JD, Lalani G, Trayanova NA. 2008. Action potential dynamics explain arrhythmic vulnerability in human heart failure: a clinical andmodeling study implicating abnormal calcium handling. J. Am. Coll. Cardiol. 52:1782-92
113. Bers DM. 2002. Cardiac excitation-contraction coupling. Nature 415:198-205
114. Wehrens XH, Lehnart SE,Marks AR. 2005. Intracellular calcium release and cardiac disease. Annu. Rev. Physiol. 67:69-98
115. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, et al. 2013. Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J. Mol. Cell. Cardiol. 61:111-22
116. Koval OM, Snyder JS, Wolf RM, Pavlovicz RE, Glynn P, et al. 2012. Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. Circulation 126:2084-94
117. Shannon TR, Bers DM. 2004. Integrated Ca2+ management in cardiac myocytes. Ann. N. Y. Acad. Sci. 1015:28-38
118. Akar FG, Wu RC, Juang GJ, Tian Y, Burysek M, et al. 2005. Molecular mechanisms underlying K+ current downregulation in canine tachycardia-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 288:H2887-96
119. Grandi E, Puglisi JL, Wagner S, Maier LS, Severi S, Bers DM. 2007. Simulation of Ca-calmodulindependent protein kinase II on rabbit ventricular myocyte ion currents and action potentials. Biophys. J. 93:3835-47
120. Reiken S, Gaburjakova M, Guatimosim S, Gomez AM, D'Armiento J, et al. 2003. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J. Biol. Chem. 278:444-53
121. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. 2004. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ. Res. 94:e61-70
122. Xiao B, Zhong G, Obayashi M, Yang D, Chen K, et al. 2006. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon β-Adrenergic stimulation in normal and failing hearts. Biochem. J. 396:7-16
123. Fischer TH, Herting J, Tirilomis T, Renner A,Neef S, et al. 2013. Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation 128:970-81
124. Marx SO,Reiken S,Hisamatsu Y, JayaramanT, BurkhoffD, et al. 2000.PKAphosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365-76
125. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. 2005. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ. Res. 97:1314-22
126. Curran J,HintonMJ, Rios E, Bers DM, Shannon TR. 2007.β-Adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes ismediated by calcium/calmodulin-dependent protein kinase. Circ. Res. 100:391-98
127. Shannon TR, Pogwizd SM, Bers DM. 2003. Elevated sarcoplasmic reticulum Ca2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ. Res. 93:592-94
128. Pogwizd SM, Bers DM. 2002. Na/Ca exchange in heart failure: contractile dysfunction and arrhythmogenesis. Ann. N. Y. Acad. Sci. 976:454-65
129. Pogwizd SM, Hoyt RH, Saffitz JE, Corr PB, Cox JL, Cain ME. 1992. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 86:1872-87
130. Pogwizd SM,McKenzie JP, Cain ME. 1998. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 98:2404-14
131. Bers DM, Pogwizd SM, Schlotthauer K. 2002. Upregulated Na/Ca exchange is involved in both contractile dysfunction and arrhythmogenesis in heart failure. Basic Res. Cardiol. 97(Suppl. 1):I36-42
132. Beuckelmann DJ, NabauerM,Erdmann E. 1993. Alterations ofK+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ. Res. 73:379-85
133. Curran J, Brown KH, Santiago DJ, Pogwizd S, Bers DM, Shannon TR. 2010. Spontaneous Ca waves in ventricular myocytes from failing hearts depend on Ca2+-calmodulin-dependent protein kinase II. J. Mol. Cell. Cardiol. 49:25-32
134. Ravens U, Cerbai E. 2008. Role of potassium currents in cardiac arrhythmias. Europace 10:1133-37
135. Nagado T, Arimura K, Sonoda Y, Kurono A, Horikiri Y, et al. 1999. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122(Part 11):2057-66
136. Hart IK,Waters C, Vincent A, Newland C, Beeson D, et al. 1997. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann. Neurol. 41:238-46
137. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, et al. 2001. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124:2417-26
138. ShihWH, Landau ME, Barner KC, Campbell WW. 2003. Acquired neuromyotonia in association with systemic lupus erythematosus. J. Clin. Neuromuscul. Dis. 5:8-11